The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

Inclusion Criteria:

• Patients with newly diagnosed stage I-IV breast cancer (tumor size

  • 2cm in imaging examinations) who are scheduled to start systemic therapy.
• Patients must have histological diagnosis of invasive breast cancer.
• Extent of disease will be determined by physical examination and conventional radiological studies.
• Must be age 18 or older.
• ECOG performance status 0-2.
• Patients with history of prior malignancies must be disease-free for at least 5 years of study entry.
• Normal hematological function: WBC > 3000/ul, absolute neutrophil count > 1500/ul, platelets > 100,000/ul, and Hgb > 10 gms (transfusion to achieve Hgb > 10 gms is acceptable).
• Serum total bilirubin < 1.5 mg/dl and SGPT < 1.5 X normal.
• Adequate kidney function (creatinine < 1.5 mg/dL).

Exclusion Criteria:

• Patients who received previous chemotherapy for the newly diagnosed breast cancer.
• No evidence of primary breast lesion (e.g. T0, Tx).
• Pregnant women or sexually active women of childbearing potential who are not practicing adequate contraception are excluded.
• Patients with myocardial infarction within 6 months of study entry; unstable angina pectoris; uncontrolled congestive heart failure; uncontrolled arrhythmia are excluded.
• Patients with history of hypersensitivity/allergy to Chitosan/Chitin related shellfish foods.